Five simple, accurate, precise, rapid, and specific stability indicating RP-HPLC methods were developed and validated for the estimation of Abacavir, Tenofovir, Emtricitabine, Efavirenz and Nelfinavir in bulk and in pharmaceutical (Tablets and capsule) dosage forms. The mobile phase used were water: Acetonitrile [80:20 %( v/v)], Acetonitrile: water [78:22 %( v/v)], Buffer: Acetonitrile [85:15 %( v/v)], Acetonitrile: Phosphate Buffer [58:42 %( v/v)], Acetonitrile: Phosphate Buffer [85:15 %( v/v)] respectively. The flow rate of 1.0 ml/min was maintained for all the methods and the effluents were detected at 285nm, 260nm, 280nm, 247nm and 220nm respectively by using a UV detector. The retention time of Abacavir, Tenofovir, Emtricitabine, Efavirenz and Nelfinavir were 7.761±0.032 minutes, 5.54±0.04 minutes, 9.34±0.08 minutes, 4.61±0.02 minutes, and 6.75±0.02 minutes respectively. Linearity was observed over concentration range of 100-2800 ng/ml, 500-4000 ng/ml, 20-600 µg/ml, 500-10000 ng/ml and 50-20000 ng/ml respectively. The Limit of detection was found to be 21.04 ng/ml while quantification limit was 63.77 ng/ml for Abacavir, 74.80 ng/ml and 226.68 ng/ml for Tenofovir, 5.539 µg/ml and 16.786 µg/ml for Emtricitabine, 157.63 ng/ml and 477.68 ng/ml for Efavirenz and 6.26 ng/ml and 18.98 ng/ml for Nelfinavir respectively.

The percentage recovery of bulk drugs and formulations (Tablets and capsule) were found to be in 98.23 to 100.61 %, 98.46 to 100.00 %, 99.46 % to 101.11 %, 98.24 to 101.17 % and 98.93 to 100.41 % respectively. The developed methods were validated according to ICH guidelines and the methods are also applicable to stability studies.

**KEYWORDS**: Abacavir, Tenofovir, Emtricitabine, Efavirenz, Nelfinavir, RP-HPLC, Stability studies, Validation, ICH guidelines.